Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease, advancing therapies on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm.
Our lead product candidate, momelotinib, is a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor currently under investigation for the treatment of myelofibrosis. Myelofibrosis results from dysregulated JAK-STAT signaling and is characterized by constitutional symptoms, an enlarged spleen and progressive anemia. Topline data from the MOMENTUM clinical trial—a global, randomized, double-blind Phase 3 study for symptomatic and anemic myelofibrosis patients—are anticipated by February 2022. The US Food & Drug Administration has granted Fast Track designation for momelotinib.
In August 2021 we in-licensed SRA515 (formerly AZD5153), a selective BRD4 BET inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains. Preclinical and early clinical data suggest SRA515 is a differentiated BET inhibitor through its high potency, selectivity, and bivalent binding, which may offer more complete target inhibition relative to monovalent binders. Initiation of a Phase 2 clinical trial evaluating the combination of momelotinib and SRA515 is planned for the first half of 2022. The trial will be designed to provide preliminary proof of concept for a future confirmatory study and support potential additional studies of momelotinib with other novel agents in development for myelofibrosis.